PBAC's latest decision on Verteporfin: Recommended with restriction (2005). Considered for Treatment of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration where the CNV is composed predominantly (≥50%) of classic lesions, as defined by fluorescein angiography.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$75k/QALY
Range: $45k/QALY–$75k/QALY
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
Patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration where the CNV is composed predominantly (≥50%) of classic lesions as defined by fluorescein angiography.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Loss of less than 15 letters of visual acuity
Key trials
TAP (Treatment of Age-Related Macular Degeneration With Photodynamic Therapy), VIP (Verteporfin in Photodynamic Therapy)